Press Release
APWG eCrime 2025 Symposium Expands Research Space to Include Cyber-Physical Threats Against People, Places and Critical Infrastructure
Pre-eminent Peer-Reviewed Cybercrime Conference Examines Physical Impact of Cybercrime Driven by AI Innovations -- Underwritten by a Newly Wealthy Criminal Culture Read More
Press Release
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis - - Raised $2.55 million in gross proceeds from a private placement financing in January 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and certain members of the Company's board of directors - Read More
Press Release
